{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:03Z","timestamp":1787028723894,"version":"build-2736575974"},"reference-count":157,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["W1253-B24 doctoral program HOROS"],"award-info":[{"award-number":["W1253-B24 doctoral program HOROS"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>There is a need for new antifungal agents, mainly due to increased incidence of invasive fungal infections (IFI), high frequency of associated morbidity and mortality and limitations of the current antifungal agents (e.g., toxicity, drug\u2013drug interactions, and resistance). The clinically available antifungals for IFI are restricted to four main classes: polyenes, flucytosine, triazoles, and echinocandins. Several antifungals are hampered by multiple resistance mechanisms being present in fungi. Consequently, novel antifungal agents with new targets and modified chemical structures are required to combat fungal infections. This review will describe novel antifungals, with a focus on the Aspergillus species.<\/jats:p>","DOI":"10.3390\/jof6040213","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T10:19:23Z","timestamp":1602238763000},"page":"213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Novel Antifungal Agents and Their Activity against Aspergillus Species"],"prefix":"10.3390","volume":"6","author":[{"given":"Roya","family":"Vahedi-Shahandashti","sequence":"first","affiliation":[{"name":"Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-7785","authenticated-orcid":false,"given":"Cornelia","family":"Lass-Fl\u00f6rl","sequence":"additional","affiliation":[{"name":"Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bongomin, F., Gago, S., Oladele, R.O., and Denning, D.W. (2017). Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi (Basel), 3.","DOI":"10.3390\/jof3040057"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden Killers: Human Fungal Infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki218","article-title":"Changing patterns and trends in systemic fungal infections","volume":"56","author":"Richardson","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s15010-017-1072-6","article-title":"Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: A 12-year experience","volume":"45","author":"Aigner","year":"2017","journal-title":"Infection"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cmi.2017.05.022","article-title":"Diagnosing fungal infections in haematology patients\u2014Another case of less is more in the clinical setting?","volume":"23","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001\u20132006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2011002","DOI":"10.4084\/mjhid.2011.002","article-title":"Update on the laboratory diagnosis of invasive fungal infections","volume":"3","author":"Posteraro","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_8","first-page":"183","article-title":"Epidemiology of opportunistic invasive mycoses","volume":"7","author":"Kullberg","year":"2002","journal-title":"Eur. J. Med. Res."},{"key":"ref_9","first-page":"a019786","article-title":"Aspergillus fumigatus and related species","volume":"5","author":"Sugui","year":"2014","journal-title":"Csh. Perspect. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/2047-783X-16-4-153","article-title":"Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature","volume":"16","author":"Mayr","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1469-0691.2009.02929.x","article-title":"Trends in invasive fungal infections, with emphasis on invasive aspergillosis","volume":"15","author":"Erjavec","year":"2009","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"a019703","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gintjee, T., Donnelley, M., and Thompson, G. (2020). Aspiring antifungals: Review of current antifungal pipeline developments. J. Fungi (Basel), 6.","DOI":"10.3390\/jof6010028"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious disease\u2019s society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections","volume":"71","year":"2011","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1517\/14656566.2015.1083976","article-title":"Treatment of drug-resistant Aspergillus infection","volume":"16","author":"Aigner","year":"2015","journal-title":"Expert Opin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fmicb.2018.00516","article-title":"Azole-resistance in Aspergillus terreus and related species: An emerging problem or a rare phenomenon?","volume":"9","author":"Zoran","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/myc.12469","article-title":"Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus","volume":"59","author":"Souza","year":"2016","journal-title":"Mycoses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jac\/dkw095","article-title":"T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2","volume":"71","author":"Nishikawa","year":"2016","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dkq177","article-title":"Uptake of T-2307, a novel arylamidine, in Candida albicans","volume":"65","author":"Nishikawa","year":"2010","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2011","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ja.2016.107","article-title":"ASP2397: A novel antifungal agent produced by Acremonium persicinum MF-347833","volume":"70","author":"Nakamura","year":"2016","journal-title":"J. Antibiot. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e02689-18","DOI":"10.1128\/AAC.02689-18","article-title":"ASP2397 Is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.02336-15","article-title":"In vitro activity of ASP2397 against Aspergillus isolates with or without acquired azole resistance mechanisms","volume":"60","author":"Arendrup","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dkx410","article-title":"Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus","volume":"73","author":"Wiederhold","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","first-page":"1","article-title":"It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug","volume":"3","author":"Scorzoni","year":"2012","journal-title":"Front. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.fgb.2019.103247","article-title":"Antifungal resistance in Aspergillus terreus: A current scenario","volume":"131","year":"2019","journal-title":"Fungal Genet. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/acs.bioconjchem.5b00463","article-title":"Taming amphotericin B","volume":"26","author":"Janout","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral aochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/bc500277v","article-title":"Molecular Umbrella\u2013Amphotericin B conjugates","volume":"25","author":"Janout","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2174\/1389201015666140706160709","article-title":"Development and characterization of amphotericin B nanosuspensions for oral administration through a simple top-down method","volume":"15","author":"Yang","year":"2014","journal-title":"Curr. Pharm. Biotechno."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1021\/acs.jmedchem.5b01862","article-title":"Novel water-soluble amphotericin B-PEG conjugates with low toxicity and potent in vivo efficacy","volume":"59","author":"Halperin","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1021\/bm5002125","article-title":"Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide","volume":"15","author":"Ickowicz","year":"2014","journal-title":"Biomacromolecules"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2147\/nano.2006.1.4.417","article-title":"Optimizing efficacy of amphotericin B through nanomodification","volume":"1","author":"Vyas","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/21505594.2016.1201250","article-title":"Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach","volume":"8","author":"Juvvadi","year":"2016","journal-title":"Virulence"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.fbr.2014.02.004","article-title":"Calcineurin as a multifunctional regulator: Unraveling novel functions in fungal stress responses, hyphal growth, drug resistance, and pathogenesis","volume":"28","author":"Juvvadi","year":"2014","journal-title":"Fungal Biol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1128\/AAC.01510-15","article-title":"In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms","volume":"59","author":"Gao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lee, Y., Lee, K., Lee, S., Beom, J., Hwangbo, A., Jung, J., Song, M., Yoo, Y., Kang, S., and Averette, A. (2018). In vitro and in vivo assessment of FK506 analogs as novel antifungal drug candidates. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01627-18"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/jac\/dku549","article-title":"Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species","volume":"70","author":"Lamoth","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/00007890-199457120-00001","article-title":"The antimicrobial activities of cyclosporine, FK506, and rapamycin","volume":"27","author":"High","year":"1994","journal-title":"Transplantation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1379\/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2","article-title":"Geldanamycin: The prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones","volume":"6","author":"Ochel","year":"2001","journal-title":"Cell Stress Chaperones"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.celrep.2012.08.035","article-title":"Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance","volume":"2","author":"Robbins","year":"2012","journal-title":"Cell Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nm.2175","article-title":"Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy","volume":"16","author":"Wurtele","year":"2010","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2016","journal-title":"J. Antibiot."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/AAC.00027-12","article-title":"The presence of an FKS mutation rather than mic is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata","volume":"56","author":"Shields","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel Echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Sandison, T., De Anda, C., Fang, E., Das, A., and Prokocimer, P. (2017). Clinical response of Tedizolid versus Linezolid in acute bacterial skin and skin structure infections by severity measure using a pooled analysis from two phase 3 double-blind trials. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02687-16"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1128\/AAC.00432-11","article-title":"Discovery of a novel class of orally active antifungal \u03b2-1,3-d-glucan synthase inhibitors","volume":"55","author":"Walker","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","first-page":"1248","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus Species Isolates","volume":"58","author":"Paderu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","first-page":"163","article-title":"Yeast sphingolipids: Metabolism and biology","volume":"1585","author":"Obeid","year":"2002","journal-title":"BBA-Mol. Cell. Biol. L"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.plipres.2015.11.003","article-title":"Plasma membrane lipids and their role in fungal virulence","volume":"61","author":"Rella","year":"2016","journal-title":"Prog. Lipid Res."},{"key":"ref_64","first-page":"14","article-title":"Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity","volume":"6","author":"Sentandreu","year":"2005","journal-title":"FEMS Yeast Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4155\/fmc-2016-0053","article-title":"Sphingolipids as targets for treatment of fungal infections","volume":"8","author":"Singh","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00546","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"7","author":"Miesel","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Ortigosa, C., Moore, C., Denning, D., and Perlin, D. (2017). Emergence of echinocandin resistance due to a point mutation in the fks1 gene of Aspergillus fumigatus in a patient with chronic pulmonary aspergillosis. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01277-17"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/AAC.00917-07","article-title":"A ser678pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus","volume":"51","author":"Rocha","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1178636119897034","article-title":"Echinocandin resistance in Aspergillus fumigatus has broad implications for membrane lipid perturbations that influence drug-target interactions","volume":"12","author":"Satish","year":"2019","journal-title":"Microbiol. Insights"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1207","article-title":"SCY-078 Demonstrates significant antifungal activity in a murine model of invasive aspergillosis","volume":"4","author":"Barat","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","article-title":"Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.00355-10","article-title":"T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena","volume":"54","author":"Yamada","year":"2010","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/AAC.04228-14","article-title":"The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2014","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hodges, M., Ople, E., Shaw, K., Mansbach, R., van Marle, S.S., van Hoogdalem, E., Kramer, W., and Wedel, P. (2017). Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability, IDweek.","DOI":"10.1093\/ofid\/ofx163.1390"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Samalova, M., Carr, P., Bromley, M., Blatzer, M., Moya-Nilges, M., Latg\u00e9, J., and Mouyna, I. (2020). GPI anchored proteins in Aspergillus fumigatus and cell wall morphogenesis. Curr. Top. Microbiol. Immunol., 167\u2013186.","DOI":"10.1007\/82_2020_207"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"23639","DOI":"10.1074\/jbc.M301044200","article-title":"GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast","volume":"278","author":"Umemura","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1209","article-title":"Absorption, Distribution, and excretion of 14c-apx001 after single-dose administration to rats and monkeys","volume":"4","author":"Mansbach","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e00969-19","DOI":"10.1128\/AAC.00969-19","article-title":"First-in-human phase 1 study to assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults","volume":"63","author":"Mammen","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","unstructured":"Vical Pharmaceutics (2019, July 27). Development of VL-2397 as an Antifungal Drug Candidate to Treat Invasive Fungal Infections. Available online: http:\/\/s1.q4cdn.com\/508380786\/files\/doc_downloads\/VL2397_ASM_Microbe_2017\/Sullivan_ASM_Microbe_2017_Oral_Presentation.pdf."},{"key":"ref_81","unstructured":"(2019, July 27). ClinicalTrials.gov. VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03327727."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.phyto.45.062806.094338","article-title":"Siderophores in fungal physiology and virulence","volume":"46","author":"Haas","year":"2008","journal-title":"Annu. Rev. Phytopathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"26723","DOI":"10.1074\/jbc.270.45.26723","article-title":"Siderophores: Structure and function of microbial iron transport compounds","volume":"270","author":"Neilands","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1074\/jbc.275.14.10709","article-title":"Desferrioxamine-mediated iron uptake in Saccharomyces cerevisiae","volume":"275","author":"Yun","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_85","unstructured":"Nakamura, I., Ohsumi, K., Yoshikawa, K., Kanasaki, R., Masaki, T., Takase, S., Hashimoto, M., Fujie, A., Nakai, T., and Matsumoto, S. (2014, January 17\u201321). ASP2397: A novel natural product with potent fungicidal activity against Aspergillus spp. (1)\u2014A new mode of action and in vitro activity. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aap7999","article-title":"Worldwide emergence of resistance to antifungal drugs challenges human health and food security","volume":"360","author":"Fisher","year":"2018","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Seyedmousavi, S., Chang, Y., Law, D., Birch, M., Rex, J., and Kwon-Chung, K. (2019). Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00129-19"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152106774755554","article-title":"Azoles: Mode of antifungal action and resistance development. effect of miconazole on endogenous reactive oxygen species production in Candida albicans","volume":"5","author":"Francois","year":"2006","journal-title":"Anti-Infect. Agents Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2017.06.037","article-title":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hargrove, T., Garvey, E., Hoekstra, W., Yates, C., Wawrzak, Z., Rachakonda, G., Villalta, F., and Lepesheva, G. (2017). Crystal structure of the new investigational drug candidate vt-1598 in complex with Aspergillus fumigatus sterol 14\u03b1-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00570-17"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/mmy\/myz092","article-title":"The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis","volume":"58","author":"Garvey","year":"2019","journal-title":"Med. Mycol. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"38461","DOI":"10.1074\/jbc.M304089200","article-title":"Fig1p facilitates Ca2+ influx and cell fusion during mating of Saccharomyces cerevisiae","volume":"278","author":"Muller","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"26256","DOI":"10.1074\/jbc.M113.494815","article-title":"Essential role for vacuolar acidification in Candida albicans virulence","volume":"288","author":"Patenaude","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00018-008-8409-3","article-title":"RTA2 is involved in calcineurin-mediated azole resistance and sphingoid long-chain base release in Candida albicans","volume":"66","author":"Jia","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2958.2002.03165.x","article-title":"Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling","volume":"46","author":"Edlind","year":"2002","journal-title":"Mol. Microbiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1128\/EC.00139-06","article-title":"Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus","volume":"5","author":"Steinbach","year":"2006","journal-title":"Eukaryot. Cell"},{"key":"ref_97","first-page":"192","article-title":"Teaching old drugs new tricks: Reincarnating immunosuppressants as antifungal drugs","volume":"4","author":"Blankenship","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_98","first-page":"310","article-title":"Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus","volume":"42","author":"Lamoth","year":"2014","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.biochem.75.103004.142738","article-title":"Structure and mechanism of the Hsp90 molecular chaperone machinery","volume":"75","author":"Pearl","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"18473","DOI":"10.1074\/jbc.R800007200","article-title":"The Hsp90 chaperone machinery","volume":"283","author":"Wandinger","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1126\/science.1118370","article-title":"Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi","volume":"309","author":"Cowen","year":"2005","journal-title":"Science"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1469-0691.2012.03848.x","article-title":"In vitro and in vivo role of heat shock protein 90 in amphotericin B resistance of Aspergillus terreus","volume":"19","author":"Blum","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fmicb.2015.00096","article-title":"Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis","volume":"6","author":"Lamoth","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1128\/EC.00274-06","article-title":"Genetic architecture of Hsp90-dependent drug resistance","volume":"5","author":"Cowen","year":"2006","journal-title":"Eukaryot. Cell"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1073\/pnas.0813394106","article-title":"Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease","volume":"106","author":"Cowen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Singh, S., Robbins, N., Zaas, A., Schell, W., Perfect, J., and Cowen, L. (2009). Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000532"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J. Antibiot."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jac\/42.6.747","article-title":"Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains","volume":"42","author":"Maesaki","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01397-07","article-title":"Synergistic Effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms","volume":"52","author":"Uppuluri","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.48.5.1664-1669.2004","article-title":"In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus","volume":"48","author":"Steinbach","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/infdis\/175.1.222","article-title":"Invasive aspergillosis in mice immunosuppressed with cyclosporin a, tacrolimus (FK506), or sirolimus (rapamycin)","volume":"175","author":"High","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/infdis\/172.6.1554","article-title":"Interferon-and tumor necrosis factor- protect mice from invasive aspergillosis","volume":"172","author":"Nagai","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_113","first-page":"372","article-title":"Production of Cyclosporine A by Submerged Fermentation","volume":"74","author":"Anjum","year":"2015","journal-title":"Fungal Metabol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkg090","article-title":"Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species","volume":"51","author":"Kontoyiannis","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.20010","article-title":"Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest","volume":"109","author":"Bedin","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1128\/AAC.01857-12","article-title":"In vitro activity of calcineurin and heat shock protein 90 inhibitors against Aspergillus fumigatus Azole- and Echinocandin-resistant strains","volume":"57","author":"Lamoth","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/AAC.02286-13","article-title":"Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus","volume":"58","author":"Lamoth","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1128\/JCM.00618-09","article-title":"Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens","volume":"47","author":"Pfaller","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"35149","DOI":"10.1074\/jbc.M111.250506","article-title":"Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens","volume":"286","author":"Hast","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Mor, V., Rella, A., Farnoud, A., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J., Ojima, I., and Bullesbach, E. (2015). Identification of a new class of antifungals targeting the synthesis of fungal sphingolipids. mBio, 6.","DOI":"10.1128\/mBio.00647-15"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/MCB.23.1.163-177.2003","article-title":"Induction of apoptosis by sphingoid long-chain bases in Aspergillus nidulans","volume":"23","author":"Cheng","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"ref_122","first-page":"13","article-title":"Sphingolipid functions in Saccharomyces cerevisiae","volume":"1583","author":"Dickson","year":"2002","journal-title":"BBA-Mol. Cell. Biol. L"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/AAC.44.3.651-653.2000","article-title":"Inhibition of inositol phosphorylceramide synthase by aureobasidin in Candida and Aspergillus Species","volume":"44","author":"Zhong","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-5793(02)03067-3","article-title":"Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc:ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth","volume":"525","author":"Levery","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/13543784.9.8.1787","article-title":"Antifungals targeted to sphingolipid synthesis: Focus on inositol phosphorylceramide synthase","volume":"9","author":"Georgopapadakou","year":"2000","journal-title":"Expert Opin. Inv. Drug"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-5793(04)00156-5","article-title":"Glucosylceramides in colletotrichum gloeosporioides are involved in the differentiation of conidia into mycelial cells","volume":"561","author":"Rodrigues","year":"2004","journal-title":"FEBS Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0014-5793(98)00967-3","article-title":"Distribution and functional diversification of the ras super family in Saccharomyces cerevisiae","volume":"434","author":"Valencia","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1128\/MCB.25.15.6722-6733.2005","article-title":"Individual palmitoyl residues serve distinct roles in H-Ras trafficking, microlocalization, and signaling","volume":"25","author":"Roy","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fmicb.2015.00128","article-title":"Exploration of Aspergillus fumigatus Ras pathways for novel antifungal drug targets","volume":"6","author":"Abdallah","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4172\/2165-8056.1000105","article-title":"Ras-mediated signal transduction and virulence in human pathogenic fungi","volume":"2","author":"Fortwendel","year":"2012","journal-title":"Fungal Genom. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1073\/pnas.1116510109","article-title":"Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity","volume":"109","author":"Maurer","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1634\/theoncologist.10-8-565","article-title":"Development of farnesyl transferase inhibitors: A review","volume":"10","author":"Appels","year":"2005","journal-title":"Oncologist"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.fgb.2003.10.004","article-title":"Aspergillus fumigatus rasA and rasB regulate the timing and morphology of asexual development","volume":"41","author":"Fortwendel","year":"2004","journal-title":"Fungal. Genet. Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/mr.48.1.42-59.1984","article-title":"Regulation of trehalose mobilization in fungi","volume":"48","author":"Thevelein","year":"1984","journal-title":"Microbiol. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/glycob\/cwg047","article-title":"New insights on trehalose: A multifunctional molecule","volume":"13","author":"Elbein","year":"2003","journal-title":"Glycobiology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e00053-16","DOI":"10.1128\/MMBR.00053-16","article-title":"Central role of the trehalose biosynthesis pathway in the pathogenesis of human fungal infections: Opportunities and challenges for therapeutic development","volume":"81","author":"Thammahong","year":"2017","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1128\/IAI.00565-09","article-title":"The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii","volume":"77","author":"Ngamskulrungroj","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/21505594.2016.1195529","article-title":"Trehalose pathway as an antifungal target","volume":"8","author":"Perfect","year":"2016","journal-title":"Virulence"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1099\/00221287-147-7-1851","article-title":"Trehalose is required for the acquisition of tolerance to a variety of stresses in the filamentous fungus Aspergillus nidulans The GenBank accession number for the sequence reported in this paper is AF043230","volume":"147","author":"Fillinger","year":"2001","journal-title":"Microbiology"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Svanstr\u00f6m, \u00c5., van Leeuwen, M., Dijksterhuis, J., and Melin, P. (2014). Trehalose synthesis in Aspergillus niger: Characterization of six homologous genes, all with conserved orthologs in related species. BMC Microbiol., 14.","DOI":"10.1186\/1471-2180-14-90"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1128\/IAI.00813-09","article-title":"Role of trehalose biosynthesis in Aspergillus fumigatus development, stress response, and virulence","volume":"78","author":"Vanier","year":"2010","journal-title":"Infect. Immun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e00244-19","DOI":"10.1128\/mSphere.00244-19","article-title":"An Ssd1 homolog impacts trehalose and chitin biosynthesis and contributes to virulence in Aspergillus fumigatus","volume":"4","author":"Thammahong","year":"2019","journal-title":"Msphere"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/MMBR.62.4.1264-1300.1998","article-title":"MAP kinase pathways in the yeast Saccharomyces cerevisiae","volume":"62","author":"Gustin","year":"1988","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.7624781","article-title":"Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor","volume":"269","author":"Maeda","year":"1995","journal-title":"Science"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1074\/jbc.270.25.14843","article-title":"How MAP kinases are regulated","volume":"270","author":"Cobb","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11046-012-9557-4","article-title":"HOG-MAPK signaling regulates the adaptive responses of Aspergillus fumigatus to thermal stress and other related stress","volume":"174","author":"Ji","year":"2012","journal-title":"Mycopathologia"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11046-012-9600-5","article-title":"Current understanding of HOG-MAPK pathway in Aspergillus fumigatus","volume":"175","author":"Ma","year":"2012","journal-title":"Mycopathologia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/EC.00323-08","article-title":"Master and commander in fungal pathogens: The two-component system and the HOG signaling pathway","volume":"7","author":"Bahn","year":"2008","journal-title":"Eukaryot. Cell"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1099\/jmm.0.050963-0","article-title":"The fungicide fludioxonil antagonizes fluconazole activity in the human fungal pathogen Candida albicans","volume":"61","author":"Buschart","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1099\/mic.0.28571-0","article-title":"Calcineurin, Mpk1 and Hog1 MAPK pathways independently control fludioxonil antifungal sensitivity in Cryptococcus neoformans","volume":"152","author":"Kojima","year":"2006","journal-title":"Microbiology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1439-0434.2001.00617.x","article-title":"Phenylpyrrole Fungicides: Mitotic Instability in Aspergillus nidulans and Resistance in Botrytis cinerea","volume":"149","author":"Ziogas","year":"2001","journal-title":"J. Phytopathol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/np030096l","article-title":"Natural products as sources of new drugs over the period 1981\u22122002","volume":"66","author":"Newman","year":"2003","journal-title":"J. Nat. Prod."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrd3074","article-title":"An insight into the antifungal pipeline: Selected new molecules and beyond","volume":"9","author":"Casadevall","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Donadu, M., Usai, D., Marchetti, M., Usai, M., Mazzarello, V., Molicotti, P., Montesu, M., Delogu, G., and Zanetti, S. (2019). Antifungal activity of oils macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis. Nat. Prod. Res.","DOI":"10.1080\/14786419.2018.1557175"},{"key":"ref_155","first-page":"153","article-title":"Antifungal and antiaflatoxigenic activity of rosemary essential oil (Rosmarinus officinalis L.) against Aspergillus flavus","volume":"37","author":"Kohiyama","year":"2019","journal-title":"Food Addit. Contam. Part A"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Powers, C., Satyal, P., Mayo, J., McFeeters, H., and McFeeters, R. (2019). Bigger data approach to analysis of essential oils and their antifungal activity against Aspergillus niger, Candida albicans, and Cryptococcus neoformans. Molecules, 24.","DOI":"10.3390\/molecules24162868"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1128\/AAC.00683-15","article-title":"Hitting the caspofungin salvage pathway of human-pathogenic fungi with the novel lasso peptide Humidimycin (MDN-0010)","volume":"59","author":"Valiante","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:17:59Z","timestamp":1760177879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":157,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jof6040213"],"URL":"https:\/\/doi.org\/10.3390\/jof6040213","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]}}}